List view / Grid view
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.
Circulating cell-free DNA (cfDNA) has been shown to have potential as a noninvasive substrate for the detection and monitoring of tumour cells. As circulating tumour DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection.
Many bioanalytical labs work with a crowded and siloed set of systems and processes. From part electronic to part paper-based workflows to standalone point-solutions, the result is a lack of insight into data and slower reporting and results handling.
Drug target identification has a key role in the drug discovery value chain. A critical step in the development of pharmaceuticals is identifying the direct targets of potential drug candidates as well as distinguishing any secondary or off-target effects...
Reporter gene assays have greatly helped our understanding of gene regulation and signal transduction in vitro and in vivo.
YEATS domains are epigenetic regulators and are recognised as readers of histone post-translational modifications (HPTM) alongside bromodomains, PHD fingers, and others.
This application note highlights the direct optic bottom reading performance of the BMG LABTECH microplate readers in two different cell-based fluorescence intensity assays from Invitrogen.
This application note discusses how the ADP-Glo™ Kinase assay is a universal, homogeneous, high-throughput screening method that measures kinase activity by quantifying the amount of ADP produced during the kinase reaction.
This application note aims to demonstrate the benefits of using orthogonal approaches for studying Staphylococcus aureus biofilms—in particular, their susceptibility to antimicrobial agents...
Multiplexing AlphaLISA type assays will increase throughput while sample expenditure and costs are minimised. The ability of the PHERAstar FS microplate reader to perform simultaneous dual emission detection of this assay will allow users to double the information obtained from each well in the same amount of time as needed…
High throughput screening is mostly done in pharmaceutical companies that test whole libraries of compounds. Reducing the assay volume will reduce operating costs. At the same time it is necessary to prove that the smaller volume will not have a negative impact on assay sensitivity and reliability.
Due to the crucial role of G protein-coupled receptors (GPCRs) in mediating cellular responses to external stimuli, these receptors have been and will remain a prime focus for medical research and the pharmaceutical industry for many years to come. Their importance is especially highlighted by the statistic that 30-50% of…
6 September 2018 | By Takara Bio
The data presented in this application note demonstrates how SMARTer ICELL8 Single-Cell System can be used to generate high-quality RNA-seq libraries that provide full-length transcript sequence information from hundreds of single cells in parallel...
Cancer immunotherapy utilises components of the immune system to treat cancer patients. These therapies are designed to work with a patient’s immune system to increase native anti-tumour responses. One type of immunotherapy relies on antibodies to bind to and inhibit the function of proteins expressed by the cancer cell...
